vardenafil Lilly
This is a summary of the European public assessment report (EPAR) for vardenafil Lilly. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use vardenafil Lilly.
For practical information about using vardenafil Lilly, patients should read the package leaflet or contact their doctor or pharmacist.
vardenafil Lilly is a medicine used to treat men with erectile dysfunction (sometimes called impotence).
It can also be used in men to treat the signs and symptoms of benign prostatic hyperplasia (enlarged prostate gland that is not cancerous, which leads to problems with the flow of urine).
vardenafil Lilly contains the active substance vardenafil and is the same as levitra, which is already authorised in the European Union (EU). The company that makes levitra has agreed that its scientific data can be used for vardenafil Lilly (‘informed consent’).
vardenafil Lilly is available as tablets (2.5, 5, 10 and 20 mg) to be taken by mouth. For erectile dysfunction, the usual dose is 10 mg at least 30 minutes before sexual activity. The dose may be increased to 20 mg if the 10 mg dose is not effective. Men who intend to use vardenafil Lilly frequently (twice a week or more) can take a lower dose (5 or 2.5 mg) once a day, based on the doctor’s judgement. The medicine should be taken around the same time every day and the need for the once-a-day dosing should be assessed regularly.
In men with benign prostatic hyperplasia, or both benign prostatic hyperplasia and erectile dysfunction, the recommended dose is 5 mg once a day.
The medicine can only be obtained with a prescription. For further information, see the package leaflet.
The active substance of vardenafil Lilly, vardenafil, belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors. It works by blocking the phosphodiesterase enzyme, which normally breaks down a substance known as cyclic guanosine monophosphate (cGMP).
During normal sexual stimulation, cGMP is produced in the penis, where it causes the muscle in the spongy tissue of the penis (the corpora cavernosa) to relax, allowing the flow of blood into the corpora, producing the erection. By blocking the breakdown of cGMP, vardenafil Lilly restores erectile function during sexual stimulation and also improves the blood flow to, and relaxes the muscles of, the prostate and bladder. This may reduce the problems with the flow of urine which are symptoms of benign prostatic hyperplasia.
vardenafil Lilly has been shown to improve the ability to get and maintain an erection in nine main studies involving over 2,000 men with erectile dysfunction. All the studies compared vardenafil Lilly with placebo (a dummy treatment) and measured improvements using questionnaires completed before and after treatment.
Six of the studies included 1,328 patients who took the medicine before sexual activity. Results for one of the questionnaires, in which men rated their condition on a scale of 0 (indicating severe erectile dysfunction) to 30 (no erectile dysfunction), showed that patients improved from about 15 before treatment, to 23 and 25 after treatment with vardenafil Lilly 10 and 20 mg, respectively. The other three studies included 853 patients taking vardenafil Lilly once a day at doses of 2.5 or 5 mg. Results also reported improved erections with vardenafil Lilly compared with those taking placebo.
vardenafil Lilly has also been shown to improve the symptoms of benign prostatic hyperplasia as measured using the international prostate symptom score (IPSS), which ranges from 0 (no symptoms) to 35 (severe symptoms). In four main studies involving 1,500 patients, some of whom also had erectile dysfunction, patients taking vardenafil Lilly at a dose of 5 mg had greater reductions in IPSS (4.8 to 6.3 points) after 12 weeks than those taking placebo (2.2 to 4.4 points).
The most common side effects with vardenafil Lilly are headache, indigestion, back pain and muscle pain, which are more common at higher doses. For the full list of all side effects with vardenafil Lilly, see the package leaflet.
vardenafil Lilly must not be used in men with certain cardiovascular (heart and blood vessel) conditions or when sexual activity is inadvisable. It must also not be taken by patients who have ever had loss of vision in one eye because of a problem with blood flow to the nerve in the eye (non-arteritic anterior ischemic optic neuropathy, NAION). vardenafil Lilly must not be taken with nitrates (a type of medicine used for angina) or medicines of the class ‘guanylate cyclase stimulators’ such as riociguat (a medicine for Pharmacy Nebenwirkungen Herzinfarkt farmacias en chile que venden levitra Tablets Timing In Urdu in the vessels supplying the lungs, known as pulmonary hypertension). For the full list of restrictions, see the package leaflet.
As shown in studies, vardenafil Lilly is effective at improving the ability to get and maintain erections and at relieving the symptoms of benign prostatic hyperplasia. The side effects seen with the medicine are considered manageable. The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore concluded that vardenafil Lilly’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of vardenafil Lilly have been included in the summary of product characteristics and the package leaflet.
The European Commission granted a marketing authorisation valid throughout the European Union for vardenafil Lilly on 22 March 2017.
For more information about treatment with vardenafil Lilly, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
It can also be used in men to treat the signs and symptoms of benign prostatic hyperplasia (enlarged prostate gland that is not cancerous, which leads to problems with the flow of urine).
vardenafil Lilly
This is a summary of the European public assessment report (EPAR) for vardenafil Lilly. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use vardenafil Lilly.
For practical information about using vardenafil Lilly, patients should read the package leaflet or contact their doctor or pharmacist.
vardenafil Lilly is a medicine used to treat men with erectile dysfunction (sometimes called impotence).
It can also be used in men to treat the signs and symptoms of benign prostatic hyperplasia (enlarged prostate gland that is not cancerous, which leads to problems with the flow of urine).
vardenafil Lilly contains the active substance vardenafil and is the same as levitra, which is already authorised in the European Union (EU). The company that makes levitra has agreed that its scientific data can be used for vardenafil Lilly (‘informed consent’).
vardenafil Lilly is available as tablets (2.5, 5, 10 and 20 mg) to be taken by mouth. For erectile dysfunction, the usual dose is 10 mg at least 30 minutes before sexual activity. The dose may be increased to 20 mg if the 10 mg dose is not effective. Men who intend to use vardenafil Lilly frequently (twice a week or more) can take a lower dose (5 or 2.5 mg) once a day, based on the doctor’s judgement. The medicine should be taken around the same time every day and the need for the once-a-day dosing should be assessed regularly.
In men with benign prostatic hyperplasia, or both benign prostatic hyperplasia and erectile dysfunction, the recommended dose is 5 mg once a day.
The medicine can only be obtained with a prescription. For further information, see the package leaflet.
The active substance of vardenafil Lilly, vardenafil, belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors. It works by blocking the phosphodiesterase enzyme, which normally breaks down a substance known as cyclic guanosine monophosphate (cGMP).
During normal sexual stimulation, cGMP is produced in the penis, where it causes the muscle in the spongy tissue of the penis (the corpora cavernosa) to relax, allowing the flow of blood into the corpora, producing the erection. By blocking the breakdown of cGMP, vardenafil Lilly restores erectile function during sexual stimulation and also improves the blood flow to, and relaxes the muscles of, the prostate and bladder. This may reduce the problems with the flow of urine which are symptoms of benign prostatic hyperplasia.
vardenafil Lilly has been shown to improve the ability to get and maintain an erection in nine main studies involving over 2,000 men with erectile dysfunction. All the studies compared vardenafil Lilly with placebo (a dummy treatment) and measured improvements using questionnaires completed before and after treatment.
Six of the studies included 1,328 patients who took the medicine before sexual activity. Results for one of the questionnaires, in which men rated their condition on a scale of 0 (indicating severe erectile dysfunction) to 30 (no erectile dysfunction), showed that patients improved from about 15 before treatment, to 23 and 25 after treatment with vardenafil Lilly 10 and 20 mg, respectively. The other three studies included 853 patients taking vardenafil Lilly once a day at doses of 2.5 or 5 mg. Results also reported improved erections with vardenafil Lilly compared with those taking placebo.
vardenafil Lilly has also been shown to improve the symptoms of benign prostatic hyperplasia as measured using the international prostate symptom score (IPSS), which ranges from 0 (no symptoms) to 35 (severe symptoms). In four main studies involving 1,500 patients, some of whom also had erectile dysfunction, patients taking vardenafil Lilly at a dose of 5 mg had greater reductions in IPSS (4.8 to 6.3 points) after 12 weeks than those taking placebo (2.2 to 4.4 points).
The most common side effects with vardenafil Lilly are headache, indigestion, back pain and muscle pain, which are more common at higher doses. For the full list of all side effects with vardenafil Lilly, see the package leaflet.
vardenafil Lilly must not be used in men with certain cardiovascular (heart and blood vessel) conditions or when sexual activity is inadvisable. It must also not be taken by patients who have ever had loss of vision in one eye because of a problem with blood flow to the nerve in the eye (non-arteritic anterior ischemic optic neuropathy, NAION). vardenafil Lilly must not be taken with nitrates (a type of medicine used for angina) or medicines of the class ‘guanylate cyclase stimulators’ such as riociguat (a medicine for Side Effect Of Pharmacy Tablet generic vardenafil review Cialis Drug Class in the vessels supplying the lungs, known as pulmonary hypertension). For the full list of restrictions, see the package leaflet.
As shown in studies, vardenafil Lilly is effective at improving the ability to get and maintain erections and at relieving the symptoms of benign prostatic hyperplasia. The side effects seen with the medicine are considered manageable. The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore concluded that vardenafil Lilly’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of vardenafil Lilly have been included in the summary of product characteristics and the package leaflet.
The European Commission granted a marketing authorisation valid throughout the European Union for vardenafil Lilly on 22 March 2017.
For more information about treatment with vardenafil Lilly, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
vardenafil Lilly must not be used in men with certain cardiovascular (heart and blood vessel) conditions or when sexual activity is inadvisable. It must also not be taken by patients who have ever had loss of vision in one eye because of a problem with blood flow to the nerve in the eye (non-arteritic anterior ischemic optic neuropathy, NAION). vardenafil Lilly must not be taken with nitrates (a type of medicine used for angina) or medicines of the class ‘guanylate cyclase stimulators’ such as riociguat (a medicine for Death Due To Pharmacy Overdose viagra vs levitra vs cialis side effects E Uso De Alcool in the vessels supplying the lungs, known as pulmonary hypertension). For the full list of restrictions, see the package leaflet.
vardenafil Lilly contains the active substance vardenafil and is the same as levitra, which is already authorised in the European Union EU.
02.07.2021 07:00:21
2021-07-02 07:00:21
This is a summary of the European public assessment report (EPAR) for vardenafil Lilly. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use vardenafil Lilly.